Beta-cell function in type 2 diabetic patients who failed to maintain good glycemic status with a combination of maximum dosages of metformin and sulfonylurea

References

• Aquilante CL . Sulfonylurea pharmacogenomics in type 2 diabetes: the influence of drug target and diabetes risk polymorphisms. Expert Rev Cardiovasc Ther . 2010;8(3):359–372. doi:10.1586/erc.09.154 20222815
   PubMedGoogle Scholar
• U.K. Prospective Diabetes Study 16. Overview of 6 years‘ therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes . 1995;44(11):1249–1258.7589820
   PubMed Web of Science ®Google Scholar
• Pantalone KM , Hobbs TM , Wells BJ , et al. Changes in characteristics and treatment patterns of patients with newly diagnosed type 2 diabetes in a large united states integrated health system between 2008 and 2013. Clin Med Insights Endocrinol Diabetes . 2016;9:23–30. doi:10.4137/CMED.S39761 27398040
   PubMedGoogle Scholar
• American Diabetes Association. 7. Approaches to glycemic treatment. Diabetes Care . 2016;39(Suppl 1):S52–S59. doi:10.2337/dc16-S010 26696682
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines on Second- and Third-Line Medicines and Type of Insulin for the Control of Blood Glucose Levels in Non-Pregnant Adults with Diabetes Mellitus . Geneva: World Health Organization; 2018 Available from www.who.int/diabetes/publications/guidelines-diabetes-medicines/en. AccessedSeptember 13, 2018.
   Google Scholar
• Davies MJ , D‘Alessio DA , Fradkin J , et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia . 2018;61(12):2461–2498. doi:10.1007/s00125-018-4729-5 30288571
   PubMed Web of Science ®Google Scholar
• Pontiroli AE , Calderara A , Pozza G . Secondary failure of oral hypoglycaemic agents: frequency, possible causes, and management. Diabetes Metab Rev . 1994;10(1):31–43.7956674
   PubMed Web of Science ®Google Scholar
• Matthews DR , Cull CA , Stratton IM , Holman RR , Turner RC . UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabetic Med . 1998;15(4):297–303. doi:10.1002/(SICI)1096-9136(199804)15:4<297::AID-DIA572>3.0.CO;2-W 9585394
   PubMed Web of Science ®Google Scholar
• Rosengren A , Jing X , Eliasson L , Renstrom E . Why treatment fails in type 2 diabetes. PLoS Med . 2008;5(10):e215. doi:10.1371/journal.pmed.0050215 18959474
   PubMed Web of Science ®Google Scholar
• Alberti KG , Zimmet PZ . Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Med . 1998;15(7):539–553. doi:10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S 9686693
   PubMed Web of Science ®Google Scholar
• Pacini G , Mari A . Methods for clinical assessment of insulin sensitivity and beta-cell function. Best Pract Res Clin Endocrinol Metab . 2003;17(3):305–322. doi:10.1016/S1521-690X(03)00042-3 12962688
   PubMed Web of Science ®Google Scholar
• Matsuda M , DeFronzo RA . Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care . 1999;22(9):1462–1470.10480510
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018. Diabetes Care . 2018;41(Suppl 1):S73–S85. doi:10.2337/dc18-S008 29222379
   PubMed Web of Science ®Google Scholar
• Pontiroli AE , Calderara A , Maffi P , et al. Secondary failure to oral hypoglycaemic agents in non-obese patients with non-insulin-dependent diabetes is related to reduced insulin release. Diabete Metab . 1989;15(2):79–84.2661281
   PubMed Web of Science ®Google Scholar
• Butler AE , Janson J , Bonner-Weir S , Ritzel R , Rizza RA , Butler PC . Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes . 2003;52(1):102–110.12502499
   PubMed Web of Science ®Google Scholar
• Takahashi A , Nagashima K , Hamasaki A , et al. Sulfonylurea and glinide reduce insulin content, functional expression of K(ATP) channels, and accelerate apoptotic beta-cell death in the chronic phase. Diabetes Res Clin Pract . 2007;77(3):343–350. doi:10.1016/j.diabres.2006.12.021 17316868
   PubMed Web of Science ®Google Scholar
• Brennan L , Hewage C , Malthouse JP , McClenaghan NH , Flatt PR , Newsholme P . Investigation of the effects of sulfonylurea exposure on pancreatic beta cell metabolism. FEBS J . 2006;273(22):5160–5168. doi:10.1111/j.1742-4658.2006.05513.x 17054712
   PubMed Web of Science ®Google Scholar
• Remedi MS , Nichols CG , Groop L . Chronic antidiabetic sulfonylureas in vivo: reversible effects on mouse pancreatic beta-cells. PLoS Med . 2008;5(10):e206. doi:10.1371/journal.pmed.0050206 18959471
   PubMed Web of Science ®Google Scholar
• Karam JH , Sanz N , Salamon E , Nolte MS . Selective unresponsiveness of pancreatic beta-cells to acute sulfonylurea stimulation during sulfonylurea therapy in NIDDM. Diabetes . 1986;35(12):1314–1320.3533680
   PubMed Web of Science ®Google Scholar
• Muller G . The molecular mechanism of the insulin-mimetic/sensitizing activity of the antidiabetic sulfonylurea drug Amaryl. Mol med . 2000;6(11):907–933.11147570
   PubMed Web of Science ®Google Scholar
• Pernet A , Trimble ER , Kuntschen F , Assal JP , Hahn C , Renold AE . Sulfonylureas in insulin-dependent (type I) diabetes: evidence for an extrapancreatic effect in vivo. J Clin Endocrinol Metab . 1985;61(2):247–251. doi:10.1210/jcem-61-2-247 3924948
   PubMed Web of Science ®Google Scholar
• Keller U , Muller R , Berger W . Sulfonylurea therapy fails to diminish insulin resistance in type I-diabetic subjects. Horm Metab Res . 1986;18(9):599–603. doi:10.1055/s-2007-1012384 2946637
   PubMed Web of Science ®Google Scholar
• Maedler K , Carr RD , Bosco D , Zuellig RA , Berney T , Donath MY . Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab . 2005;90(1):501–506. doi:10.1210/jc.2004-0699 15483097
   PubMed Web of Science ®Google Scholar
• Donath MY , Ehses JA , Maedler K , et al. Mechanisms of β-cell death in type 2 diabetes. Diabetes . 2005;54(suppl2):S108–S113.16306327
   PubMed Web of Science ®Google Scholar
• Grunberger G . Maintenance of sulfonylurea responsiveness in NIDDM. Randomized double-blind study of intermittent glyburide therapy. Diabetes Care . 1992;15(5):696–699.1516489
   PubMed Web of Science ®Google Scholar
• Garber AJ , Abrahamson MJ , Barzilay JI , et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2017 executive summary. Endocr Pract . 2017;23(2):207–238. doi:10.4158/EP161682.CS 28095040
   PubMed Web of Science ®Google Scholar
• Vos RC , van Avendonk MJ , Jansen H , et al. Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control. Cochrane Database Syst Rev . 2016;9:CD006992.27640062
   PubMed Web of Science ®Google Scholar
• Nyback-Nakell A , Adamson U , Lins PE , Landstedt-Hallin L . Glycaemic responsiveness to long-term insulin plus sulphonylurea therapy as assessed by sulphonylurea withdrawal. Diabetic Med . 2007;24(12):1424–1429. doi:10.1111/j.1464-5491.2007.02286.x 17976204
   PubMed Web of Science ®Google Scholar
• Srivanichakorn W , Sriwijitkamol A , Kongchoo A , et al. Withdrawal of sulfonylureas from patients with type 2 diabetes receiving long-term sulfonylurea and insulin combination therapy results in deterioration of glycemic control: a randomized controlled trial. Diabetes Metab Syndr Obes . 2015;8:137–145. doi:10.2147/DMSO.S78008 25767401
   PubMed Web of Science ®Google Scholar
• Yokoyama H , Sone H , Yamada D , Honjo J , Haneda M . Contribution of glimepiride to basal-prandial insulin therapy in patients with type 2 diabetes. Diabetes Res Clin Pract . 2011;91(2):148–153. doi:10.1016/j.diabres.2010.10.007 21067837
   PubMed Web of Science ®Google Scholar
• Nyback-Nakell A , Adamson U , Lins PE , Landstedt-Hallin L . Adding glimepiride to insulin+metformin in type 2 diabetes of more than 10 years‘ duration–a randomised, double-blind, placebo-controlled, cross-over study. Diabetes Res Clin Pract . 2014;103(2):286–291. doi:10.1016/j.diabres.2013.12.062 24485398
   PubMed Web of Science ®Google Scholar
• Yoon KH , Lee JH , Kim JW , et al. Epidemic obesity and type 2 diabetes in Asia. Lancet . 2006;368(9548):1681–1688. doi:10.1016/S0140-6736(06)69703-1 17098087
   PubMed Web of Science ®Google Scholar